Last reviewed · How we verify

CICAPROST — Competitive Intelligence Brief

CICAPROST (CICAPROST) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: cicaprost. Area: Hematology.

phase 2 cicaprost Prostacyclin receptor, Prostaglandin D2 receptor, Prostaglandin E2 receptor EP1 subtype Hematology Small molecule Live · refreshed every 30 min

Target snapshot

CICAPROST (CICAPROST). Cicaprost works by binding to and activating the prostacyclin receptor, mimicking the effects of prostacyclin to promote vasodilation and inhibit platelet aggregation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CICAPROST TARGET CICAPROST phase 2 cicaprost Prostacyclin receptor, Prostaglandin D2 receptor, Prostaglandin E2 receptor EP1 subtype

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (cicaprost class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CICAPROST — Competitive Intelligence Brief. https://druglandscape.com/ci/cicaprost. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing